Leizorovicz A, Siguret V, Mottier D, et al; Innohep in Renal Insufficiency Study Steering Committee. Safety profile of tinzaparin versus subcutaneous unfractionated heparin in elderly patients with impaired renal function treated for acute deep vein thrombosis: the Innohep in Renal Insufficiency Study (IRIS). Thromb Res. 2011;128(1):27-34. 86. Bazinet A, Almanric K, Brunet C, et al. Dosage of enoxaparin among obese and renal impairment patients. Thromb Res. 2005;116(1):41-50. 87. Chow SL, Zammit K, West K, Dannenhoffer M, Lopez-Candales A. Correlation of antifactor Xa concentrations with renal function in patients on enoxaparin. J Clin Pharmacol. 2003;43(6):586-590. 88. Kruse MW, Lee JJ. Retrospective evaluation of a pharmacokinetic program for adjusting enoxaparin in renal impairment. Am Heart J. 2004;148(4): 582-589. 89. Pautas E, Gouin I, Bellot O, Andreux JP, Siguret V. Safety profile of tinzaparin administered once daily at a standard curative dose in two hundred very elderly patients. Drug Saf. 2002;25(10):725-733. 90. Peng YG, Eikelboom JW, Tenni P, McQuillan A, Thorne J. Renal function, peak anti Xa levels and enoxaparin dosing. J Pharm Pract Res. 2004; 34(1):14-17. 91. Siguret V, Pautas E, Fe vrier M, et al. Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU/kg): anti-Xa and anti-IIa activities over 10 days. Thromb Haemost. 2000;84(5):800-804. 92. Sule AA, Tay JC, Arul E. Effect of enoxaparin on peak and trough levels of antifactor Xa in patients with a creatinine clearance of less than 30 mL/min. Int J Angiol. 2009;18(4):184-186. 93. Ballew A, Lee Y, Vega J, Duong HN. Evaluating current recommended dose of enoxaparin in renally impaired and morbidly obese patients by monitoring anti-factor Xa levels [abstract]. Pharmacotherapy. 2014;34(10):e273-e274. 94. Lachish T, Rudensky B, Slotki I, Zevin S. Enoxaparin dosage adjustment in patients with severe renal failure: antifactor xa concentrations and safety. Pharmacotherapy. 2007;27(10):1347-1352. 95. 